. 2020 Mar;8(6):282. doi: 10.21037/atm.2020.03.30

Table 2. Relationship between SLC16A1 level and clinicopathologic features (N=33).

Characteristics	No. of patients		PYGM △Ct^a, mean ± SD	Non-parametric test value	P value
Characteristics	No.	%	PYGM △Ct^a, mean ± SD	Non-parametric test value	P value
Age (years)
<60	10	30.3	60.96±86.49	Z =−0.838	0.402
≥60	23	69.7	44.32±100.29	Z =−0.838	0.402
Gender
Female	10	30.3	49.21±88.17	Z =−0.627	0.531
Male	23	69.7	52.32±97.82	Z =−0.627	0.531
Smoking history
Nonsmoker	21	63.6	22.68±15.68	Z =−2.330	0.026
Smoker	12	36.4	95.53±139.66	Z =−2.330	0.026
Alcohol history
Nondrinker	23	69.7	26.42±18.62	Z =−2.136	0.041
Drinker	10	30.3	95.06±146.97	Z =−2.136	0.041
Tumor size (cm)
≤4	23	69.7	45.42±69.25	Z =−0.353	0.724
>4	10	30.3	65.09±138.38	Z =−0.353	0.724
Lymph node metastasis
pN0	23	69.7	43.44±71.20	Z =−0.726	0.468
pN1 to pN2	10	30.3	67.26±130.36	Z =−0.726	0.468
TNM stage
I-II	17	51.5	53.47±81.80	Z =−0.108	0.914
III-IV	16	48.5	49.41±106.07	Z =−0.108	0.914
Pathological differentiation
Well	30	90.9	40.34±61.77	Z =−2.277	0.030
Moderately/poorly	3	9.1	161.75±254.64	Z =−2.277	0.030
Disease site
Tongue	11	33.3	25.09±18.19	H =1.871	0.143
Gingival	8	24.2	24.23±10.43
Cheek	8	24.2	10.83±5.65
Floor of mouth	2	3.0	39.83±24.57
Oropharynx	4	12.1	15.61±14.93
Recurrence
No	26	78.8	60.17±103.95	Z =−1.321	0.186
Yes	7	21.2	18.74±12.53	Z =−1.321	0.186

SD, standard deviation; pN, pathological lymph node status; TNM stage, tumor-lymph node-metastasis stage. ^a△Ct indicates the difference in the cycle number at which a sample’s fluorescent signal passes a given threshold above baseline (Ct) derived from a specific gene compared with that of β-actin in tumor tissues.